Edgewood Oncology Analysis

What is Edgewood Oncology?

Edgewood Oncology is a clinical-stage biotechnology company dedicated to developing BTX-A51 for patients with significant unmet medical needs. The company targets master regulators of cancer to activate programmed cell death, demonstrating promising clinical activity and a favorable safety profile. Their focus includes hematologic malignancies and genetically-defined solid tumors.

Product Features & Capabilities

• BTX-A51, a small molecule multi-kinase inhibitor